Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Hartford Hospital
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01919086
First received: August 7, 2013
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)